The performance was transmitted live to the 33rd Annual Live Interventions in Vascular Endotherapy (Singapore Live 2024), in conjunction with the 13th CTO Interventions Live Course 2024 on January 25-27
Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
January 28, 2021
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease.
SINGAPORE, January 28, 2021 /EINPresswire.com/ Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, recently presented at 30th Annual Live Interventions in Vascular Endotherapy conference organised by the National Heart Centre of Singapore (Singapore LIVE). The bioadaptor is the first coronary artery implant that adapts to vessel physiology.